Abstract
Oxidative damage is shown to affect every class of biological macromolecule in Alzheimer disease. Disruptions in iron and copper homeostasis are understood as being key players in neurodegenerative disease pathogenesis. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed here with its relations to oxidative stress. While there is substantial documented evidence for alterations in transition metal metabolism, redox-activity and localization, it is also important to note that alterations in specific copper- and iron-containing metalloenzymes also contribute to the neurodegenerative process. Understanding these changes offers the opportunity to identify pathways where modification of the disease process can offer effective clinical intervention, from gene therapy to pharmaceuticals with antioxidant and chelating properties.
Keywords: neurodegenerative disease, antioxidant, chelating properties, pathogenesis of alzheimer disease, copper homeostasis, iron mediated oxidative damage
Current Medicinal Chemistry
Title: Therapeutic Potential in Alzheimer Disease
Volume: 9 Issue: 17
Author(s): A. D. Cash, G. Perry and M. A. Smith
Affiliation:
Keywords: neurodegenerative disease, antioxidant, chelating properties, pathogenesis of alzheimer disease, copper homeostasis, iron mediated oxidative damage
Abstract: Oxidative damage is shown to affect every class of biological macromolecule in Alzheimer disease. Disruptions in iron and copper homeostasis are understood as being key players in neurodegenerative disease pathogenesis. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed here with its relations to oxidative stress. While there is substantial documented evidence for alterations in transition metal metabolism, redox-activity and localization, it is also important to note that alterations in specific copper- and iron-containing metalloenzymes also contribute to the neurodegenerative process. Understanding these changes offers the opportunity to identify pathways where modification of the disease process can offer effective clinical intervention, from gene therapy to pharmaceuticals with antioxidant and chelating properties.
Export Options
About this article
Cite this article as:
Cash D. A., Perry G. and Smith A. M., Therapeutic Potential in Alzheimer Disease, Current Medicinal Chemistry 2002; 9 (17) . https://dx.doi.org/10.2174/0929867023369411
DOI https://dx.doi.org/10.2174/0929867023369411 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proline-Rich Peptides: Multifunctional Bioactive Molecules as New Potential Therapeutic Drugs
Current Protein & Peptide Science Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Editorial (Thematic Issue: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications)
CNS & Neurological Disorders - Drug Targets The ASK1-MAP Kinase Signaling in ER Stress and Neurodegenerative Diseases
Current Molecular Medicine Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research Autophagy Regulators as Potential Cancer Therapeutic agents: A Review
Current Topics in Medicinal Chemistry Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimers Disease: Progress and Problems
Current Pharmaceutical Design Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?
Current Pharmaceutical Design Editorial [Hot Topic: New Prospects for Treatment of Autoimmune Diseases (Executive Guest Editor: Alessandra Fierabracci)]
Current Pharmaceutical Design Biopharmaceutical Characterization, Metabolism, and Brain Penetration of the Triple Reuptake Inhibitor Amitifadine
Drug Metabolism Letters FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT)
Current Alzheimer Research Quinoline Derivatives: Candidate Drugs for a Class B G-Protein Coupled Receptor, the Calcitonin Gene-Related Peptide Receptor, a Cause of Migraines
CNS & Neurological Disorders - Drug Targets Antioxidant Properties of Ferulic Acid Salts with Nicotine, Thionicotine and Selenonicotine
Letters in Organic Chemistry Heterogeneity of Cholecystokinin Receptors: A New Interest Towards the Development of CCK2 Agonists
Current Medicinal Chemistry - Central Nervous System Agents Diversity Oriented p-TSA Catalyzed Efficient and Environmentally Benign Synthetic Protocol for the Synthesis of Structurally Diverse Heteroannulated Benzothiazolopyrimidines
Current Organocatalysis MicroRNA-130b Promotes Wear Particle-Induced Osteolysis via Downregulating Frizzled-Related Protein (FRZB)
Current Neurovascular Research Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine